2024 World Conference on Lung Cancer (WCLC) - Posters-P1.06B.05 Utility of Molecular Tumor Board Driven by Precision Medicine Service and Cloud-Based Datamart for Therapy and Trial Matching

P1.06B.05 Utility of Molecular Tumor Board Driven by Precision Medicine Service and Cloud-Based Datamart for Therapy and Trial Matching

Back to course

Pdf Summary

The study presented focuses on the clinical utility of a Precision Medicine (PM) service and a Molecular Tumor Board (MTB), enhanced by a cloud-based data mart, in optimizing therapy and clinical trial matching for cancer patients. Conducted at the H. Lee Moffitt Cancer Center & Research Institute, this approach leverages a data mart that processes genomics and patient information to streamline recommendations for targeted therapy and clinical trials. Data ingestion is automated from electronic health records (EHR) and next-generation sequencing (NGS) results into a cloud-based platform, Moffitt Cancer Analytics Platform (MCAP), which supports data curation and integration.<br /><br />Between July and December 2023, the PM-MTB approach was assessed through 364 cases involving 323 unique patients, mostly diagnosed with lung cancer. Of these, 73% had stage IV disease, with adenocarcinoma being prevalent. Over the period studied, actionable genetic alterations, like EGFR and KRAS mutations, were identified in 38.8% of patients, enabling targeted therapy. 29.3% were suitable for on-label therapy, while 9.5% were eligible for off-label treatments.<br /><br />Moreover, the system identified clinical trial opportunities for 57% of the patients, with 60 enrolling in trials, underscoring the platform's role in facilitating trial recruitment. An identified challenge in precision oncology is the complexities of interpreting molecular results, which this system addresses by enabling real-time interpretations and decision-making for patient treatment pathways. <br /><br />The study concludes that the PM-MTB model, backed by a cloud-based data mart, offers a scalable, sustainable solution to incorporating precision medicine into routine clinical practice, addressing real-world challenges and optimizing patient outcomes through targeted therapies and trial match facilitation. This underscores the significant impacts and utility of integrating technology into oncology care provision.

Asset Subtitle

J. Hicks

Meta Tag

Speaker J. Hicks

Topic Pathology & Biomarkers

Keywords

Precision Medicine

Molecular Tumor Board

Cancer Therapy

Clinical Trials

Data Mart

Genomics

Cloud-based Platform

Targeted Therapy

Oncology

H. Lee Moffitt Cancer Center